MedTrace Logo

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

NCT00324142 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-08-02

No results posted yet for this study

Summary

This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.

Conditions

  • Recurrent Bacterial Vaginosis

Interventions

DRUG

Oral tinidazole

Sponsors & Collaborators

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Jennifer Gunter, MD · Kaiser Permamente

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00324142 on ClinicalTrials.gov